BEAM
Price
$22.83Alerts
Change
-$1.20 (-4.99%)
Updated
Nov 13 closing price
Capitalization
2.73B
107 days until earnings call
Intraday BUY SELL Signals
FHTX
Price
$2.07Alerts
Change
+$0.02 (+0.98%)
Updated
Nov 13 closing price
Capitalization
111.05M
116 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs FHTX

BEAM vs FHTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 20, 2026

Which Stock Would AI Choose? Beam Therapeutics (BEAM) vs. Foghorn Therapeutics (FHTX) Stock Comparison

Key Takeaways

  • BEAM (Beam Therapeutics) is advancing multiple late-stage precision genetic medicine programs, including an accelerated approval pathway for its lead AATD therapy.
  • FHTX (Foghorn Therapeutics) recently ended its Eli Lilly collaboration and discontinued its lead oncology candidate, triggering a sharp repricing and restructuring.
  • The two companies have markedly different risk profiles: BEAM holds roughly $1.2 billion in cash versus about $168 million for FHTX.
  • BEAM's momentum is driven by clinical and regulatory catalysts, while FHTX is refocusing on earlier-stage, wholly owned pipeline programs.
  • Recent relative performance diverged sharply, with FHTX trading near 52-week lows while BEAM showed more stable positioning.

Introduction

Biotechnology investors frequently weigh clinical-stage names against one another, and few contrasts are sharper right now than BEAM and FHTX. Both companies develop next-generation medicines, yet they occupy different ends of the risk-reward spectrum. Beam Therapeutics is building toward potential regulatory filings, while Foghorn Therapeutics is pivoting after a major pipeline setback. This stock comparison is most relevant for traders and investors who follow catalyst-driven moves in the gene-editing and oncology spaces, and who want to understand how market positioning, cash resources, and near-term events can shape relative performance.

BEAM Overview and Recent Performance

BEAM, or Beam Therapeutics, is a biotechnology company developing precision genetic medicines built around its proprietary base editing technology, which makes targeted single-letter changes to DNA without creating double-stranded breaks. The company's two principal franchises target liver diseases and blood disorders.

In recent months, Beam has delivered a series of clinical and regulatory milestones. Its lead liver program, BEAM-302 for alpha-1 antitrypsin deficiency (AATD), reported updated safety and efficacy data showing durable increases in functional AAT and reductions in the mutant Z-AAT protein. Based on feedback from the U.S. Food and Drug Administration (FDA), the company is pursuing an accelerated approval pathway and recently dosed the first patient in a global pivotal cohort. Separately, the FDA cleared an investigational new drug (IND) application for BEAM-304, a candidate for phenylketonuria (PKU), a rare metabolic disorder.

In its hematology franchise, Beam expects to submit a biologics license application (BLA) for risto-cel, its sickle cell disease therapy, as early as year-end 2026. The company reported roughly $1.2 billion in cash and marketable securities, which it projects will fund operations into mid-2029.

FHTX Overview and Recent Performance

FHTX, or Foghorn Therapeutics, is a clinical-stage biotechnology company developing medicines that target the chromatin regulatory system—the machinery that controls gene expression—through its Gene Traffic Control platform, with programs in oncology and immunology.

Recent market activity has been dominated by a significant strategic setback. After reviewing Phase 1 dose-escalation data, Foghorn and its partner Eli Lilly decided not to advance FHD-909, an experimental oral drug targeting the SMARCA2 protein, because it did not demonstrate sufficient efficacy. The companies also elected not to advance a related SMARCA2 degrader program, effectively ending the collaboration. In response, Foghorn announced an approximately 40% workforce reduction and a shift in resources toward its wholly owned pipeline, including a selective EP300 degrader, a CBP degrader, and an oral immunology and inflammation program.

The announcement pressured the shares, which fell toward 52-week lows, and prompted several analysts to cut price targets. Foghorn reported about $168 million in cash as of mid-2026, with the restructuring expected to extend its runway into the second half of 2029.

Trending AI Robots

Tickeron's Trending AI Robots page curates a focused selection from the hundreds of AI trading bots available on the platform, which collectively trade thousands of different tickers across varied strategies and timeframes. Only the bots judged most suitable for current market conditions earn a place in this section. These bots differ in trading style, holding period, risk parameters, performance statistics, and the specific sets of tickers they trade, so investors can evaluate options aligned with their own objectives. Whether you are tracking momentum in clinical-stage biotech names or seeking systematic, rules-based signals, exploring the Trending AI Robots can help you identify data-driven tools matched to today's environment.

Head-to-Head Comparison

The clearest difference between these two companies is stage and scale. BEAM is approaching potential regulatory submissions with a large cash balance and a diversified pipeline spanning liver and blood diseases. FHTX, by contrast, is a smaller-capitalization company that has just lost its anchor partnership and lead clinical asset, leaving it to lean on earlier-stage, wholly owned programs.

In terms of growth drivers, Beam's catalysts are near-term and regulatory in nature—updated clinical data, an accelerated approval pathway, and a planned BLA filing. Foghorn's catalysts are further out, with IND-enabling studies targeted for 2026 and an IND application anticipated in 2027. This timing gap is reflected in sentiment: Beam's relative performance has been more stable, while Foghorn has experienced pronounced volatility and a sharp repricing.

Risk factors also diverge. Beam faces execution risk across multiple late-stage trials but benefits from substantial financial flexibility. Foghorn faces pipeline concentration risk and a narrower cash position, though its restructuring has extended its runway. Sector exposure adds another layer—Beam sits within gene editing and genetic disease, while Foghorn is focused on oncology and immunology—meaning the two stocks respond to different clinical, regulatory, and funding dynamics.

Tickeron AI Verdict

Based on observable factors such as trend consistency, financial positioning, and the proximity of catalysts, Tickeron's AI would likely favor BEAM over FHTX in the current environment. Beam's combination of a sizable cash reserve, multiple late-stage programs, and near-term regulatory milestones suggests more consistent momentum and relatively stronger market positioning. Foghorn's sharp repricing and transition to earlier-stage assets introduce greater uncertainty and fewer immediate catalysts. As with any probabilistic assessment, the relative outlook can shift as new clinical data, regulatory decisions, and financing developments emerge.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
BEAM vs. FHTX commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and FHTX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BEAM with price predictions
Nov 13, 2026

BEAM in upward trend: 10-day moving average crossed above 50-day moving average on November 03, 2026

The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +4.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

BEAM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for BEAM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAM as a result. In 74 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for BEAM turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 40 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

BEAM moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.555) is normal, around the industry mean (3.498). P/E Ratio (-38.275) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for FHTX with price predictions
Nov 13, 2026

FHTX's RSI Oscillator recovers from oversold territory

The RSI Oscillator for FHTX moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 57 cases where FHTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for FHTX just turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.

Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHTX as a result. In 68 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.370) is normal, around the industry mean (3.498). P/E Ratio (-1.889) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. FHTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BEAM vs FHTX: Fundamental Ratings
BEAM
FHTX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
6165
P/E GROWTH RATING
1..100
468
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (5) in the null industry is in the same range as FHTX (23). This means that BEAM’s stock grew similarly to FHTX’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as FHTX (100). This means that BEAM’s stock grew similarly to FHTX’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as FHTX (100). This means that BEAM’s stock grew similarly to FHTX’s over the last 12 months.

BEAM's Price Growth Rating (61) in the null industry is in the same range as FHTX (65). This means that BEAM’s stock grew similarly to FHTX’s over the last 12 months.

FHTX's P/E Growth Rating (8) in the null industry is somewhat better than the same rating for BEAM (46). This means that FHTX’s stock grew somewhat faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMFHTX
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 26 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 5 days ago
87%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (BEAM: $22.83 vs. FHTX: $2.07)
Brand notoriety: BEAM and FHTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 99% vs. FHTX: 50%
Market capitalization -- BEAM: $2.73B vs. FHTX: $111.05M
BEAM [@Biotechnology] is valued at $2.73B. FHTX’s [@Biotechnology] market capitalization is $111.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green while FHTX’s FA Score has 2 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • FHTX’s FA Score: 2 green, 3 red.
According to our system of comparison, both BEAM and FHTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while FHTX’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • FHTX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, FHTX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -13.56% price change this week, while FHTX (@Biotechnology) price change was +10.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 02, 2027.

FHTX is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-4.99%
CRSP - BEAM
77%
Closely correlated
-0.89%
NTLA - BEAM
71%
Closely correlated
-8.06%
EDIT - BEAM
67%
Closely correlated
+1.40%
PRME - BEAM
64%
Loosely correlated
+9.77%
RXRX - BEAM
60%
Loosely correlated
-4.35%
More

FHTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with IMTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then IMTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FHTX
1D Price
Change %
FHTX100%
+0.98%
IMTX - FHTX
42%
Loosely correlated
-1.99%
ARVN - FHTX
41%
Loosely correlated
-0.73%
IMVT - FHTX
41%
Loosely correlated
-2.48%
BNTC - FHTX
39%
Loosely correlated
-0.55%
BEAM - FHTX
38%
Loosely correlated
-4.99%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MAGA57.19N/A
N/A
Truth Social America First ETF (MAGA)
HJUN25.34N/A
N/A
Corgi U.S. Equities 100% Structured Buffer ETF - June Series (HJUN)
VRIG25.06-0.01
-0.04%
Invesco Variable Rate Investment Grade ETF (VRIG)
GDE50.80-0.26
-0.51%
WisdomTree Efficient Gold Plus Equity Strategy Fund (GDE)
GXPT31.15-0.57
-1.80%
Global X PureCap MSCI Information Technology ETF (GXPT)